Charles River Laboratories International, Inc. $CRL Holdings Boosted by Crossmark Global Holdings Inc.

Key Points

• Crossmark Global Holdings increased its Charles River Laboratories stake by 197.3% in the third quarter, bringing its holdings to 12,773 shares worth approximately $3.8 million. Institutional investors and hedge funds collectively own 98.91% of CRL.
• Wall Street analysts remain broadly optimistic, with an average “Moderate Buy” rating and a consensus price target of $302.33; several firms recently raised their targets to between $322 and $340.
• Charles River exceeded quarterly earnings expectations, reporting $3.02 in EPS versus the $2.77 estimate and $1 billion in revenue, though revenue declined 2.7% year over year. Company insiders sold approximately $26.8 million of stock over the past three months.

Crossmark Global Holdings Inc. lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 197.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 12,773 shares of the medical research company's stock after purchasing an additional 8,476 shares during the period. Crossmark Global Holdings Inc.'s holdings in Charles River Laboratories International were worth $3,768,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of CRL. Amundi raised its holdings in Charles River Laboratories International by 175.2% in the 1st quarter. Amundi now owns 773,315 shares of the medical research company's stock valued at $133,397,000 after acquiring an additional 492,301 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Charles River Laboratories International by 14.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company's stock worth $285,001,000 after purchasing an additional 210,260 shares in the last quarter. Assenagon Asset Management S.A. grew its position in Charles River Laboratories International by 230.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 204,537 shares of the medical research company's stock worth $59,044,000 after purchasing an additional 142,716 shares in the last quarter. State of Alaska Department of Revenue increased its position in shares of Charles River Laboratories International by 2,268.2% during the 3rd quarter. State of Alaska Department of Revenue now owns 111,781 shares of the medical research company's stock valued at $32,977,000 after purchasing an additional 107,061 shares during the last quarter. Finally, Ranger Investment Management L.P. bought a new stake in Charles River Laboratories International in the 1st quarter valued at about $12,198,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CRL has been the topic of several research reports. Royal Bank Of Canada lifted their price target on shares of Charles River Laboratories International from $282.00 to $322.00 and gave the stock an "outperform" rating in a research note on Friday, September 25th. Morgan Stanley boosted their target price on Charles River Laboratories International from $300.00 to $340.00 and gave the stock an "overweight" rating in a report on Monday, October 12th. Jefferies Financial Group raised their price target on Charles River Laboratories International from $305.00 to $340.00 and gave the company a "buy" rating in a report on Monday, September 28th. Robert W. Baird boosted their price target on Charles River Laboratories International from $291.00 to $334.00 and gave the stock an "outperform" rating in a research note on Friday, September 25th. Finally, Sanford C. Bernstein set a $250.00 price target on Charles River Laboratories International in a report on Wednesday, July 1st. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $302.33.

Charles River Laboratories International Price Performance

Charles River Laboratories International stock opened at $345.08 on Friday. The stock has a market capitalization of $16.47 billion, a P/E ratio of -71.15, a P/E/G ratio of 3.17 and a beta of 1.40. The company's fifty day moving average price is $294.35 and its 200 day moving average price is $233.22. Charles River Laboratories International, Inc. has a 1 year low of $146.20 and a 1 year high of $351.21. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, topping analysts' consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $980.53 million. During the same quarter last year, the business posted $3.12 earnings per share. The firm's revenue was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, equities research analysts anticipate that Charles River Laboratories International, Inc. will post 11.38 earnings per share for the current fiscal year.

Insider Activity

In other Charles River Laboratories International news, CEO Birgit Girshick sold 6,500 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $279.90, for a total value of $1,819,350.00. Following the completion of the transaction, the chief executive officer directly owned 36,013 shares of the company's stock, valued at approximately $10,080,038.70. This trade represents a 15.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Victoria Creamer sold 4,179 shares of the stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $259.16, for a total value of $1,083,029.64. Following the transaction, the executive vice president directly owned 30,051 shares in the company, valued at approximately $7,788,017.16. This represents a 12.21% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 94,127 shares of company stock worth $26,776,516 over the last three months. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.